Intus Bio
Farmington
About Intus Bio
Intus Bio's breakthrough and proprietary Titan-1 platform is powering a microbiome revolution, by providing high-resolution data on a high-throughput basis. The platform is able to benefit researchers and patients alike, with its strain level data combined with advanced analysis combing for truly actionable insights and results. This platform can either be used for patient testing to help health outcomes, or for patient stratification and response prediction, study or trial de-risking and as a way to significantly improve patient safety. The company's mission is to make the microbiome as integral to healthcare as it is to our health, by generating unprecedented visibility and understanding of the bacteria in us, on us and around us.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $5.2M
- Last round: Series Unknown (May 2025)
- Website: intusbio.com
- Phone: [email protected]
Industries & Categories
Bioinformatics, Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/intus-bio-156549 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.